TrialSignal
Clinical trial intelligence report
Denosumab and Male Infertility: a Randomized Controlled Double-blinded Intervention Study
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03030196
Status
COMPLETED
Phase
PHASE2
Sponsor
Martin Blomberg Jensen
Executive brief
Investment-Ready Snapshot
To determine the significance of systemic RANKL inhibition for male reproduction, conducting a clinical controlled randomized double blinded intervention study on infertile men, to investigating whether Denosumab (Prolia) can increase semen quality and to investigate what subgroup of infertile men that might benefit from treatment.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03030196
Indication
Infertility, Male
Modality
monoclonal antibody
Target
Denosumab
Intervention
Denosumab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.